Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923838 | 0.86 | CHEK1 (0.49) | BACE1ATRDYRK1AGSK3BPIM1 | |
| SCHEMBL11924372 | 0.86 | BACE1 (0.43) | BACE1GPR119SMPD3DYRK1AMAPK8 | |
| SCHEMBL13028382 | 0.82 | BACE1 (0.46) | BACE1GPR119SMPD3DYRK1AMAPT | |
| SCHEMBL13028223 | 0.82 | GPR119 (0.46) | BACE1GPR119DYRK1AMAPTGSK3B | |
| SCHEMBL13028384 | 0.82 | GPR119 (0.44) | BACE1GPR119SMPD3DYRK1AMAPT | |
| SCHEMBL13028071 | 0.82 | BACE1 (0.47) | BACE1GPR119DYRK1AMAPTPIM1 | |
| SCHEMBL12830778 | 0.82 | CHEK1 (0.53) | BACE1ATRDYRK1AGSK3BPIM1 | |
| SCHEMBL11924366 | 0.80 | CHEK1 (0.43) | BACE1GPR119ATRDYRK1AMAPK8 | |
| SCHEMBL13028142 | 0.80 | CHEK1 (0.46) | BACE1GPR119DYRK1APIM1PIM3 | |
| SCHEMBL11924363 | 0.79 | CHEK1 (0.43) | BACE1GPR119DYRK1AMAPK8PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669259-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669259-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011025706-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208826-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | CDK1, MTOR, GAK | BACE1 767/4885GPR119 2225/4885SMPD3 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.